Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2007 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | International Braz J Urol (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000500013 |
Resumo: | OBJECTIVE: To investigate the possible protective effect of recombinant human interleukin-11 (rhIL-11) against ifosfamide (IFS)-induced hemorrhagic cystitis (HC) MATERIALS AND METHODS: Male Swiss mice (20-30g) were pretreated with rhIL-11 (25-625 mg, subcutaneously.) 30 min before intraperitoneal injection of IFS (400 mg/kg) or with saline (control group). Twelve hours later, HC was evaluated by bladder wet weight (BWW) to quantify edema, Evans blue extravasation (EBE) to measure vascular permeability, and macroscopic and microscopic analysis. All bladders were assessed by histopathological analysis RESULTS: rhIL-11 (at 125 and 625 mg) attenuated the IFS- induced increase of BWW (37.48% and 45.44%, respectively, p < 0.05) and EBE (62.35% and 56.47%, respectively, p < 0.05). IFS- induced macroscopic edema and hemorrhage and microscopic alterations, were also prevented by rhIL-11 at 625 mg. (p < 0.05) CONCLUSION: Our results demonstrate a protective effect of rhIL-11 on experimental IFS- induced HC, not previously reported. |
id |
SBU-1_b26f260dc894d3d8f17a833354aaf5aa |
---|---|
oai_identifier_str |
oai:scielo:S1677-55382007000500013 |
network_acronym_str |
SBU-1 |
network_name_str |
International Braz J Urol (Online) |
repository_id_str |
|
spelling |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitisbladderifosfamidecystitisinterleukin-11ratsOBJECTIVE: To investigate the possible protective effect of recombinant human interleukin-11 (rhIL-11) against ifosfamide (IFS)-induced hemorrhagic cystitis (HC) MATERIALS AND METHODS: Male Swiss mice (20-30g) were pretreated with rhIL-11 (25-625 mg, subcutaneously.) 30 min before intraperitoneal injection of IFS (400 mg/kg) or with saline (control group). Twelve hours later, HC was evaluated by bladder wet weight (BWW) to quantify edema, Evans blue extravasation (EBE) to measure vascular permeability, and macroscopic and microscopic analysis. All bladders were assessed by histopathological analysis RESULTS: rhIL-11 (at 125 and 625 mg) attenuated the IFS- induced increase of BWW (37.48% and 45.44%, respectively, p < 0.05) and EBE (62.35% and 56.47%, respectively, p < 0.05). IFS- induced macroscopic edema and hemorrhage and microscopic alterations, were also prevented by rhIL-11 at 625 mg. (p < 0.05) CONCLUSION: Our results demonstrate a protective effect of rhIL-11 on experimental IFS- induced HC, not previously reported.Sociedade Brasileira de Urologia2007-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000500013International braz j urol v.33 n.5 2007reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382007000500013info:eu-repo/semantics/openAccessMota,Jose M.Brito,Gerly A.Loiola,Raphael T.Cunha,Fernando Q.Ribeiro,Ronaldo de A.eng2008-02-29T00:00:00Zoai:scielo:S1677-55382007000500013Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2008-02-29T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false |
dc.title.none.fl_str_mv |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
title |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
spellingShingle |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis Mota,Jose M. bladder ifosfamide cystitis interleukin-11 rats |
title_short |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
title_full |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
title_fullStr |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
title_full_unstemmed |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
title_sort |
Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis |
author |
Mota,Jose M. |
author_facet |
Mota,Jose M. Brito,Gerly A. Loiola,Raphael T. Cunha,Fernando Q. Ribeiro,Ronaldo de A. |
author_role |
author |
author2 |
Brito,Gerly A. Loiola,Raphael T. Cunha,Fernando Q. Ribeiro,Ronaldo de A. |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Mota,Jose M. Brito,Gerly A. Loiola,Raphael T. Cunha,Fernando Q. Ribeiro,Ronaldo de A. |
dc.subject.por.fl_str_mv |
bladder ifosfamide cystitis interleukin-11 rats |
topic |
bladder ifosfamide cystitis interleukin-11 rats |
description |
OBJECTIVE: To investigate the possible protective effect of recombinant human interleukin-11 (rhIL-11) against ifosfamide (IFS)-induced hemorrhagic cystitis (HC) MATERIALS AND METHODS: Male Swiss mice (20-30g) were pretreated with rhIL-11 (25-625 mg, subcutaneously.) 30 min before intraperitoneal injection of IFS (400 mg/kg) or with saline (control group). Twelve hours later, HC was evaluated by bladder wet weight (BWW) to quantify edema, Evans blue extravasation (EBE) to measure vascular permeability, and macroscopic and microscopic analysis. All bladders were assessed by histopathological analysis RESULTS: rhIL-11 (at 125 and 625 mg) attenuated the IFS- induced increase of BWW (37.48% and 45.44%, respectively, p < 0.05) and EBE (62.35% and 56.47%, respectively, p < 0.05). IFS- induced macroscopic edema and hemorrhage and microscopic alterations, were also prevented by rhIL-11 at 625 mg. (p < 0.05) CONCLUSION: Our results demonstrate a protective effect of rhIL-11 on experimental IFS- induced HC, not previously reported. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000500013 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000500013 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1677-55382007000500013 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
dc.source.none.fl_str_mv |
International braz j urol v.33 n.5 2007 reponame:International Braz J Urol (Online) instname:Sociedade Brasileira de Urologia (SBU) instacron:SBU |
instname_str |
Sociedade Brasileira de Urologia (SBU) |
instacron_str |
SBU |
institution |
SBU |
reponame_str |
International Braz J Urol (Online) |
collection |
International Braz J Urol (Online) |
repository.name.fl_str_mv |
International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU) |
repository.mail.fl_str_mv |
||brazjurol@brazjurol.com.br |
_version_ |
1750318070520348672 |